Treatment Failure
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R.,
“Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”,
N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
tau Proteins
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R.,
“Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”,
N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
Surveys and Questionnaires
C. Reed, Happich, M., Argimon, J. Maria, Haro, J. Maria, Wimo, A., Bruno, G., Dodel, R., Jones, R. W., Vellas, B., and Belger, M.,
“What Drives Country Differences in Cost of Alzheimer's Disease? An Explanation from Resource Use in the GERAS Study.”,
J Alzheimers Dis, vol. 57, no. 3, pp. 797-812, 2017.
Societies, Medical
B. Dubois, Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. Luis, Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., Cappa, S., Crutch, S., Engelborghs, S., Frisoni, G. B., Fox, N. C., Galasko, D., Habert, M. - O., Jicha, G. A., Nordberg, A., Pasquier, F., Rabinovici, G., Robert, P., Rowe, C., Salloway, S., Sarazin, M., Epelbaum, S., de Souza, L. C., Vellas, B., Visser, P. J., Schneider, L., Stern, Y., Scheltens, P., and Cummings, J. L.,
“Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.”,
Lancet Neurol, vol. 13, no. 6, pp. 614-29, 2014.
Signal Transduction
N. Voyle, Keohane, A., Newhouse, S., Lunnon, K., Johnston, C., Soininen, H., Kloszewska, I., Mecocci, P., Tsolaki, M., Vellas, B., Lovestone, S., Hodges, A., Kiddle, S., and Dobson, R. Jb,
“A Pathway Based Classification Method for Analyzing Gene Expression for Alzheimer's Disease Diagnosis.”,
J Alzheimers Dis, vol. 49, no. 3, pp. 659-69, 2016.
Severity of Illness Index
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R.,
“Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”,
N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
Residence Characteristics
A. Jacquin-Piques, Sacco, G., Tavassoli, N., Rouaud, O., Bejot, Y., Giroud, M., Robert, P., Vellas, B., and Bonin-Guillaume, S.,
“Psychotropic Drug Prescription in Patients with Dementia: Nursing Home Residents Versus Patients Living at Home.”,
J Alzheimers Dis, vol. 49, no. 3, pp. 671-80, 2016.
Psychotropic Drugs
A. Jacquin-Piques, Sacco, G., Tavassoli, N., Rouaud, O., Bejot, Y., Giroud, M., Robert, P., Vellas, B., and Bonin-Guillaume, S.,
“Psychotropic Drug Prescription in Patients with Dementia: Nursing Home Residents Versus Patients Living at Home.”,
J Alzheimers Dis, vol. 49, no. 3, pp. 671-80, 2016.
Practice Guidelines as Topic
B. Dubois, Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. Luis, Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., Cappa, S., Crutch, S., Engelborghs, S., Frisoni, G. B., Fox, N. C., Galasko, D., Habert, M. - O., Jicha, G. A., Nordberg, A., Pasquier, F., Rabinovici, G., Robert, P., Rowe, C., Salloway, S., Sarazin, M., Epelbaum, S., de Souza, L. C., Vellas, B., Visser, P. J., Schneider, L., Stern, Y., Scheltens, P., and Cummings, J. L.,
“Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.”,
Lancet Neurol, vol. 13, no. 6, pp. 614-29, 2014.
Phenotype
B. Dubois, Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. Luis, Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., Cappa, S., Crutch, S., Engelborghs, S., Frisoni, G. B., Fox, N. C., Galasko, D., Habert, M. - O., Jicha, G. A., Nordberg, A., Pasquier, F., Rabinovici, G., Robert, P., Rowe, C., Salloway, S., Sarazin, M., Epelbaum, S., de Souza, L. C., Vellas, B., Visser, P. J., Schneider, L., Stern, Y., Scheltens, P., and Cummings, J. L.,
“Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.”,
Lancet Neurol, vol. 13, no. 6, pp. 614-29, 2014.
Oligonucleotide Array Sequence Analysis
N. Voyle, Keohane, A., Newhouse, S., Lunnon, K., Johnston, C., Soininen, H., Kloszewska, I., Mecocci, P., Tsolaki, M., Vellas, B., Lovestone, S., Hodges, A., Kiddle, S., and Dobson, R. Jb,
“A Pathway Based Classification Method for Analyzing Gene Expression for Alzheimer's Disease Diagnosis.”,
J Alzheimers Dis, vol. 49, no. 3, pp. 659-69, 2016.
Nursing Homes
A. Jacquin-Piques, Sacco, G., Tavassoli, N., Rouaud, O., Bejot, Y., Giroud, M., Robert, P., Vellas, B., and Bonin-Guillaume, S.,
“Psychotropic Drug Prescription in Patients with Dementia: Nursing Home Residents Versus Patients Living at Home.”,
J Alzheimers Dis, vol. 49, no. 3, pp. 671-80, 2016.
Neuropsychological Tests
M. Sattlecker, Khondoker, M., Proitsi, P., Williams, S., Soininen, H., Kłoszewska, I., Mecocci, P., Tsolaki, M., Vellas, B., Lovestone, S., and Dobson, R. Jb,
“Longitudinal Protein Changes in Blood Plasma Associated with the Rate of Cognitive Decline in Alzheimer's Disease.”,
J Alzheimers Dis, vol. 49, no. 4, pp. 1105-14, 2016.
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R.,
“Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”,
N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
Models, Genetic
N. Voyle, Keohane, A., Newhouse, S., Lunnon, K., Johnston, C., Soininen, H., Kloszewska, I., Mecocci, P., Tsolaki, M., Vellas, B., Lovestone, S., Hodges, A., Kiddle, S., and Dobson, R. Jb,
“A Pathway Based Classification Method for Analyzing Gene Expression for Alzheimer's Disease Diagnosis.”,
J Alzheimers Dis, vol. 49, no. 3, pp. 659-69, 2016.
Mental Status Schedule
M. Sattlecker, Khondoker, M., Proitsi, P., Williams, S., Soininen, H., Kłoszewska, I., Mecocci, P., Tsolaki, M., Vellas, B., Lovestone, S., and Dobson, R. Jb,
“Longitudinal Protein Changes in Blood Plasma Associated with the Rate of Cognitive Decline in Alzheimer's Disease.”,
J Alzheimers Dis, vol. 49, no. 4, pp. 1105-14, 2016.
Male
N. Voyle, Keohane, A., Newhouse, S., Lunnon, K., Johnston, C., Soininen, H., Kloszewska, I., Mecocci, P., Tsolaki, M., Vellas, B., Lovestone, S., Hodges, A., Kiddle, S., and Dobson, R. Jb,
“A Pathway Based Classification Method for Analyzing Gene Expression for Alzheimer's Disease Diagnosis.”,
J Alzheimers Dis, vol. 49, no. 3, pp. 659-69, 2016.
M. Sattlecker, Khondoker, M., Proitsi, P., Williams, S., Soininen, H., Kłoszewska, I., Mecocci, P., Tsolaki, M., Vellas, B., Lovestone, S., and Dobson, R. Jb,
“Longitudinal Protein Changes in Blood Plasma Associated with the Rate of Cognitive Decline in Alzheimer's Disease.”,
J Alzheimers Dis, vol. 49, no. 4, pp. 1105-14, 2016.
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R.,
“Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”,
N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
A. Jacquin-Piques, Sacco, G., Tavassoli, N., Rouaud, O., Bejot, Y., Giroud, M., Robert, P., Vellas, B., and Bonin-Guillaume, S.,
“Psychotropic Drug Prescription in Patients with Dementia: Nursing Home Residents Versus Patients Living at Home.”,
J Alzheimers Dis, vol. 49, no. 3, pp. 671-80, 2016.
C. Reed, Happich, M., Argimon, J. Maria, Haro, J. Maria, Wimo, A., Bruno, G., Dodel, R., Jones, R. W., Vellas, B., and Belger, M.,
“What Drives Country Differences in Cost of Alzheimer's Disease? An Explanation from Resource Use in the GERAS Study.”,
J Alzheimers Dis, vol. 57, no. 3, pp. 797-812, 2017.
Longitudinal Studies
M. Sattlecker, Khondoker, M., Proitsi, P., Williams, S., Soininen, H., Kłoszewska, I., Mecocci, P., Tsolaki, M., Vellas, B., Lovestone, S., and Dobson, R. Jb,
“Longitudinal Protein Changes in Blood Plasma Associated with the Rate of Cognitive Decline in Alzheimer's Disease.”,
J Alzheimers Dis, vol. 49, no. 4, pp. 1105-14, 2016.
Linear Models
M. Sattlecker, Khondoker, M., Proitsi, P., Williams, S., Soininen, H., Kłoszewska, I., Mecocci, P., Tsolaki, M., Vellas, B., Lovestone, S., and Dobson, R. Jb,
“Longitudinal Protein Changes in Blood Plasma Associated with the Rate of Cognitive Decline in Alzheimer's Disease.”,
J Alzheimers Dis, vol. 49, no. 4, pp. 1105-14, 2016.
International Cooperation
B. Dubois, Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. Luis, Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., Cappa, S., Crutch, S., Engelborghs, S., Frisoni, G. B., Fox, N. C., Galasko, D., Habert, M. - O., Jicha, G. A., Nordberg, A., Pasquier, F., Rabinovici, G., Robert, P., Rowe, C., Salloway, S., Sarazin, M., Epelbaum, S., de Souza, L. C., Vellas, B., Visser, P. J., Schneider, L., Stern, Y., Scheltens, P., and Cummings, J. L.,
“Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.”,
Lancet Neurol, vol. 13, no. 6, pp. 614-29, 2014.
C. Reed, Happich, M., Argimon, J. Maria, Haro, J. Maria, Wimo, A., Bruno, G., Dodel, R., Jones, R. W., Vellas, B., and Belger, M.,
“What Drives Country Differences in Cost of Alzheimer's Disease? An Explanation from Resource Use in the GERAS Study.”,
J Alzheimers Dis, vol. 57, no. 3, pp. 797-812, 2017.
Pages